Drugs / AZD5863
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06005493 | Jul 2023 → Jul 2027 expected | esophageal adenocarcinoma, gastric cancer, gastroesophageal cancer, pancreatic ductal adenocarcinoma | AstraZeneca | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD5863 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06005493 ↗ |
| Action | Deplete | “AZD5863 mediated T cell-dependent bystander killing of CLDN18.2-negative cells” PMID 40759445 ↗ Aug 2025 |
| Route | Intravenous | “AZD5863 monotherapy administered intravenously” NCT06005493 ↗ |